175 related articles for article (PubMed ID: 32864684)
21. Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma.
Mizuno T; Kamai T; Tsuzuki T; Nishihara D; Kijima T; Arai K; Yoshida KI
Cancer Immunol Immunother; 2022 Mar; 71(3):565-578. PubMed ID: 34275008
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays.
de Jong JJ; Stoop H; Boormans JL; van Leenders GJLH
Virchows Arch; 2021 Oct; 479(4):705-713. PubMed ID: 33909149
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma].
Campedel L; Seisen T; Cussenot O; Comperat E; Varinot J; Rouprêt M; Cancel-Tassin G
Prog Urol; 2018 Dec; 28(16):900-905. PubMed ID: 30219646
[TBL] [Abstract][Full Text] [Related]
24. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
Rüschoff J; Kumar G; Badve S; Jasani B; Krause E; Rioux-Leclercq N; Rojo F; Martini M; Cheng L; Tretiakova M; Mitchell C; Anders RA; Robert ME; Fahy D; Pyle M; Le Q; Yu L; Glass B; Baxi V; Babadjanova Z; Pratt J; Brutus S; Karasarides M; Hartmann A
Virchows Arch; 2024 Apr; 484(4):597-608. PubMed ID: 38570364
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
26. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.
Bellmunt J; Mullane SA; Werner L; Fay AP; Callea M; Leow JJ; Taplin ME; Choueiri TK; Hodi FS; Freeman GJ; Signoretti S
Ann Oncol; 2015 Apr; 26(4):812-817. PubMed ID: 25600565
[TBL] [Abstract][Full Text] [Related]
27. Cutoff values of PD-L1 expression in urinary cytology samples for predicting response to immune checkpoint inhibitor therapy in upper urinary tract urothelial carcinoma.
Chen Y; Fu J; Li Z; Chen Q; Zhang J; Yang Y; Yang P; Wang J; Liu Z; Cao Y; Zhang Y
Cancer Cytopathol; 2023 Mar; 131(3):179-187. PubMed ID: 36397276
[TBL] [Abstract][Full Text] [Related]
28. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
[TBL] [Abstract][Full Text] [Related]
29. Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients' samples.
Gulinac M; Dikov D; Velikova T; Belovezhdov V
Ann Diagn Pathol; 2020 Dec; 49():151640. PubMed ID: 33069081
[TBL] [Abstract][Full Text] [Related]
30. Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.
Kdimati S; Christoph C; Glass Ä; Engel N; Dräger DL; Maletzki C; Becker AS; Zimpfer A
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542462
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of programmed death ligand-1 and programmed death-1 expression in patients with upper tract urothelial carcinoma.
Campedel L; Compérat E; Cancel-Tassin G; Varinot J; Pfister C; Delcourt C; Gobet F; Roumiguié M; Patard PM; Daniel G; Bigot P; Carrouget J; Eymerit C; Larré S; Léon P; Durlach A; Ruffion A; de Mazancourt ES; Decaussin-Petrucci M; Bessède T; Lebacle C; Ferlicot S; Robert G; Vuong NS; Philip M; Crouzet S; Matillon X; Mège-Lechevallier F; Lang H; Mouracade P; Lindner V; Gougis P; Cussenot O; Rouprêt M; Seisen T
BJU Int; 2023 Nov; 132(5):581-590. PubMed ID: 37488983
[TBL] [Abstract][Full Text] [Related]
32. The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.
van Dijk N; Gil-Jimenez A; Silina K; van Montfoort ML; Einerhand S; Jonkman L; Voskuilen CS; Peters D; Sanders J; Lubeck Y; Broeks A; Hooijberg E; Vis DJ; van den Broek M; Wessels LFA; van Rhijn BWG; van der Heijden MS
Front Immunol; 2021; 12():793964. PubMed ID: 34987518
[TBL] [Abstract][Full Text] [Related]
33. The prognostic and clinicopathological significance of Tim-3 and PD-1 expression in the prognosis of upper urinary tract urothelial carcinoma.
Chen H; Wang M; Weng T; Wei Y; Liu C; Yang L; Ren K; Tang Y; Tang Z; Gou X
Urol Oncol; 2021 Nov; 39(11):743-753. PubMed ID: 34330653
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
35. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer.
Masuda T; Tanaka N; Takamatsu K; Hakozaki K; Takahashi R; Anno T; Kufukihara R; Shojo K; Mikami S; Shinojima T; Kakimi K; Tsunoda T; Aimono E; Nishihara H; Mizuno R; Oya M
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314433
[TBL] [Abstract][Full Text] [Related]
36. Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma.
Eich ML; Tregnago AC; Faraj SF; Palsgrove DN; Fujita K; Bezerra SM; Munari E; Sharma R; Chaux A; Netto GJ
Virchows Arch; 2019 Jan; 474(1):21-27. PubMed ID: 30338346
[TBL] [Abstract][Full Text] [Related]
37. Prognostic role of stromal tumor-infiltrating lymphocytes in locally advanced upper tract urothelial carcinoma: A retrospective multicenter study (TSU-02 study).
Cheng S; Zhong W; Xia K; Hong P; Lin R; Wang B; Li X; Chen J; Liu Z; Zhang H; Liu C; Ye L; Ma L; Lin T; Li X; Huang J; Zhou L
Oncoimmunology; 2021 Jan; 10(1):1861737. PubMed ID: 33489471
[TBL] [Abstract][Full Text] [Related]
38. Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.
Zajac M; Boothman AM; Ben Y; Gupta A; Jin X; Mistry A; Sabalos C; Nielsen A; Manriquez G; Barker C; Antal J; Wang P; Patil P; Schechter N; Rebelatto MC; Walker J
Arch Pathol Lab Med; 2019 Jun; 143(6):722-731. PubMed ID: 30457897
[TBL] [Abstract][Full Text] [Related]
39. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas.
Gonzalez-Roibon N; Albadine R; Sharma R; Faraj SF; Illei PB; Argani P; Ertoy D; Allaf ME; Netto GJ
Hum Pathol; 2013 Dec; 44(12):2651-7. PubMed ID: 24071011
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives.
Gevaert T; Cimadamore A; Montironi R; Eckstein M
Curr Drug Targets; 2021; 22(2):162-170. PubMed ID: 32386490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]